Research on colorectal and bowel cancer. Covers AI-audited colonoscopy, gut-bacteria links, family risk, and early-onset differences.
A genetic program has been identified that constructs the pipeline supplying blood and nutrients to colorectal tumors. This program involves a group of 46 genes known as tumor endothelial markers (TEMs), which are elevated tenfold or more in tumor endothelium.
A UCSD researcher has been awarded a grant to study the incidence and impact of microsatellite instability on colon cancer in African-Americans. The research aims to understand why African-Americans have a higher death rate from colorectal cancer despite lower incidence rates.
Researchers identify genetic abnormalities in microsatelite instability (MSI) and chromosomal instability (CSI) leading to varying tumor behaviors. Colorectal cancer patients with MSI form have a better chance of surviving longer, prompting potential changes in treatment strategies.
A new treatment approach combining traditional chemotherapy with medication delivered through an implanted pump has been found to significantly increase two-year survival rates and decrease tumor recurrence in patients with advanced colorectal cancer that has spread to the liver. The study, published in the New England Journal of Medic...
A new molecular biology test detected a substance in lymph nodes that may indicate future recurrence of colorectal cancer. The American College of Physicians-American Society of Internal Medicine also cautions physicians about selling products from their offices, emphasizing the need for high ethical standards.
Researchers at Thomas Jefferson University have developed a blood test to detect the spread of colorectal cancer to lymph nodes by identifying the presence of a protein called GCC. This test may help doctors diagnose the disease more accurately and provide better treatment options for patients.
Hereditary colorectal cancer tumors with high microsatellite instability (MSI) levels show a lack of genes responsible for DNA mismatch repair, vital to DNA replication. This can lead to faulty repair and colon cancer development.
Researchers at Memorial Sloan-Kettering Cancer Center found nearly 20% of young patients with colorectal cancer have the HNPCC syndrome, a dominantly inherited disorder that increases lifetime risk of developing multiple cancers. Individuals with HNPCC require special surveillance to protect against additional cancers.
A study by researchers at Ohio State University found that genes involved in detoxifying cancer-causing chemicals play a role in the development of colorectal tumors. People with certain genetic mutations tend to develop tumors at younger ages or in the distal area of the large intestine.
A multi-centered study led by Dartmouth Medical School found that supplementation with calcium can reduce the recurrence rate of large bowel adenomas in people with a history of these particular polyps. The findings suggest promising measures that are fairly simple and inexpensive to help prevent colorectal cancer.
A multi-disciplinary team at CWRU will examine the quality of life for cancer survivors aged 60+, exploring coping mechanisms and support systems. The five-year longitudinal study aims to understand how cancer survivors cope with age-related health issues.
Researchers at UT Southwestern Medical Center have developed an animal model for human colorectal cancer, which will facilitate research into the molecular mechanisms of the disease. The model, based on a colon cancer mouse, allows for testing of chemoprevention agents and new drug treatments.
Scientists found that aspirin suppresses accumulation of genetic mutations causing hereditary colorectal cancer. Aspirin screens for cells with stable genetics, potentially preventing the disease. Researchers now plan a clinical trial to study higher doses of aspirin in preventing hereditary colon cancer.
The Seattle Gastrointestinal Program Project will investigate the role of oxidative damage in pancreatitis and chronic ulcerative colitis. Researchers aim to develop screening tests for pancreatic cancer and more sensitive early detection methods for colon cancer.
A study published in Nature Medicine suggests that the diabetes drug troglitazone may increase the risk of colon cancer by activating the PPAR receptor, which promotes tumor formation in the colon. The study found that mice treated with troglitazone developed a significantly greater number of colon polyps than those not treated.
A new study finds that positron emission tomography (PET) can detect additional tumors in patients with warning signs of colorectal cancer. PET imaging confirmed disease in 15 out of 17 patients with tumors, while those with negative results remained cancer-free for at least nine months.
Researchers found that relatives of individuals with colon polyps have a slightly less than doubling of risk compared to the general population, rising to about 10-12% over a lifetime. The study suggests that these individuals should receive colonoscopy instead of sigmoidoscopy for screening.
Researchers at The Wistar Institute have identified a key role for the GA733 antigen in inhibiting colorectal cancer cell invasion. The discovery has led to the development of an antibody that increases survival rates for CRC patients.
Researchers at Rockefeller University are conducting a study to examine the potential of three plant-derived compounds - curcumin, rutin, and quercetin - to prevent colorectal cancer. The study aims to determine whether these compounds can safely inhibit the development of colon polyps and reduce cancer risk.
Researchers at Roswell Park Comprehensive Cancer Center found that p53 mutation does not trigger cancer development for colorectal cancer, contrary to long-held dogma. Instead, they identified a mysterious enigma controlling cell progression to cancerous states.
A new drug, CPT-11, has been approved by the FDA for treating colorectal cancer. Researchers plan to enroll approximately 660 patients in a Phase III trial to evaluate its effectiveness as a first-line treatment.